SCHEMBL4059477

SCHEMBL4059477

CCCCOc1ccc(C=O)c(OC)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
MAOB P27338 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.53
ERN1 O75460 3/20 0.52
CYP1A1 P04798 2/20 0.47
CYP1B1 Q16678 2/20 0.47
CYP1A2 P05177 1/20 0.47
TUBB1 Q9H4B7 1/20 0.47
THRA P10827 1/20 0.46
THRB P10828 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
DPP4 P27487 1/20 0.45
PTPN1 P18031 1/20 0.45
AHR P35869 1/20 0.45
TRIM24 O15164 1/20 0.44
TYR P14679 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13683800 0.97 ALDH1A1 (0.63) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL14195830 0.95 MAOB (0.62) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL4063273 0.95 MAOB (0.62) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL20892596 0.94 ALDH1A1 (0.67) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL4064858 0.90 ALDH1A1 (0.51) ALDH1A1MAOBL3MBTL1ERN1TDP1
SCHEMBL5654406 0.88 ALDH1A1 (0.63) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL5654410 0.88 ALDH1A1 (0.63) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL426335 0.88 ALDH1A1 (0.63) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL13191485 0.87 ALDH1A1 (0.67) ALDH1A1MAOBL3MBTL1ERN1CYP1A1
SCHEMBL15728130 0.87 TUBB1 (0.61) ALDH1A1MAOBERN1TUBB1THRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2855419-B1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-8633182-B2 Indanyloxyphenylcyclopropanecarboxylic acids BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
WO-2013178575-A1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-05 WO disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
WO-2010111353-A1 N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS ACADIA PHARMACEUTICALS, INC. (US) 2010-09-30 WO disclosed
CN-100577651-C Lactam compound and medicinal use thereof AJINOMOTO KK 2010-01-06 CN disclosed
US-7632830-B2 Lactam compounds and pharmaceutical use thereof AJINOMOTO CO., INC. (JP) 2009-12-15 US disclosed
EP-1346993-B1 LACTAM COMPOUNDS AND MEDICAL USE THEREOF AJINOMOTO KK (JP) 2009-10-21 EP disclosed
US-20080096862-A1 LACTAM COMPOUNDS AND PHARMACEUTICAL USE THEREOF AJINOMOTO CO., INC. (JP) 2008-04-24 US disclosed
US-7326701-B2 Lactam compounds and pharmaceutical use thereof AJINOMOTO CO., INC. (JP) 2008-02-05 US disclosed
CN-1911915-A Lactam compound and medicinal use thereof AJINOMOTO KK (JP) 2007-02-14 CN disclosed
US-7153850-B2 Lactam compounds and pharmaceutical use thereof AJINOMOTO CO., INC. (JP) 2006-12-26 US disclosed
US-20060189597-A1 Lactam compounds and pharmaceutical use thereof AJINOMOTO CO., INC. (JP) 2006-08-24 US disclosed
CN-1269818-C Lactam compounds and pharmaceutical use thereof AJINOMOTO KK (JP) 2006-08-16 CN disclosed
CN-1487940-A Lactam compounds and pharmaceutical use thereof ֮����ʽ���� 2004-04-07 CN disclosed
US-20040048847-A1 Lactam compounds and pharmaceutical use thereof AJINOMOTO CO. INC (JP) 2004-03-11 US disclosed
EP-1346993-A1 LACTAM COMPOUNDS AND MEDICINAL USE THEREOF Ajinomoto Co., Inc. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189597-A1 Lactam compounds and pharmaceutical use thereof SLC2A4, SLC2A8, SLC2A1 ALDH1A1 911/4885MAOB 2230/4885L3MBTL1 4773/4885
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 ALDH1A1 2410/4885MAOB 2832/4885L3MBTL1 4507/4885
US-20040048847-A1 Lactam compounds and pharmaceutical use thereof SLC2A4, SLC2A8, SLC2A1 ALDH1A1 911/4885MAOB 2230/4885L3MBTL1 4773/4885
US-20080096862-A1 LACTAM COMPOUNDS AND PHARMACEUTICAL USE THEREOF SLC2A4, SLC2A8, SLC2A1 ALDH1A1 911/4885MAOB 2230/4885L3MBTL1 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.